Despite the current widespread use of prostate-specific antigen (PSA) screening that increases the detection of PCa at an early stage when it is localised to the prostate, ∼30% of men treated with surgical or radiation therapies will relapse (Han et al, 2001). The gene discussed is KLK3; the disease is posterior cortical atrophy.